BRIEF — Scinai Expands CDMO Business With $5.1 Million Development And Clinical Manufacturing Agreement

Oct 13 (Reuters) — Scinai Immunotherapeutics Ltd: Scinai Expands Cdmo Business With $5.1 Million Development And Clinical Manufacturing Agreement Scinai Immunotherapeutics - Agreement Supports Development In 2026 And Clinical Manufacturing In 2027 Scinai Immunotherapeutics - Potential Additional Clinical Manufacturing Indicative Value $5.85 Million For Late 2027-h1 2028 Source text:... Further company coverage: 2F50y.F (Reuters.Briefs@thomsonreuters.com;)